Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2019-03-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon. Children will receive three doses of the Na-GST-1/Alhydrogel hookworm vaccine co-administered with the Na-APR-1 (M74)/Alhydrogel hookworm vaccine or the hepatitis B vaccine co-administered with sterile saline. All injections will be delivered intramuscularly (deltoid) on approximately Days 0, 56, and 112 or 180.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults

NCT03373214

Hookworm Infection Hookworm Disease

COMPLETED PHASE1

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

NCT01385189

Hookworm Infection Hookworm Disease

COMPLETED PHASE1

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975

Hookworm Infections

COMPLETED PHASE2

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

NCT02143518

Hookworm Infection Hookworm Disease

COMPLETED PHASE1

Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults

NCT03910972

Schistosomiasis Schistosoma Mansoni

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon. Children will receive three doses of the assigned vaccine(s) delivered intramuscularly (deltoid) on approximately Days 0, 56, and 112 or 180.

Safety will be measured from the time of each study vaccination (Day 0) through 14 days after each study vaccination by the occurrence of solicited injection site and systemic reactogenicity events.

Unsolicited non-serious adverse events (AEs) will be collected from the time of the first study vaccination through approximately 1 month after each study vaccination. New-onset chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time of the first study vaccination through approximately 9 months after the third study vaccination (final visit). Clinical laboratory evaluations for safety will be performed on venous blood collected approximately 14 days after each vaccination.

Immunogenicity testing will include IgG antibody responses to each vaccine antigen, by a qualified indirect enzyme-linked immunosorbent assay (ELISA), on serum or plasma obtained prior to each study vaccination and at time points after each vaccination (see Appendix A); the functional activity of vaccine-induced antibodies will be assessed by in vitro enzyme neutralization assays; the induction of B cell memory will be measured by antigen-specific memory B cell responses.

Recruitment and enrollment into the study will occur on an ongoing basis, with each group being recruited and vaccinated in sequence.

60 subjects will be enrolled into 3 groups of 20. The first 20 subjects will be assembled and enrolled into Group 1:

1. Group 1 double-blind IP allocation (n=20):

* 16 subjects will receive 10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm.

* 8 will be vaccinated according to a 0,2,4-month schedule
* 8 will be vaccinated according to a 0,2,6-month schedule
* 4 subjects will receive hepatitis B vaccine comparator:

* 2 will be vaccinated according to a 0,2,4-month schedule
* 2 will be vaccinated according to a 0,2,6-month schedule
2. Group 2 double-blind IP allocation (n=20):

* 16 subjects will receive 30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30µg Na-GST-1 administered IM in the alternate arm.

* 8 will be vaccinated according to a 0,2,4-month schedule
* 8 will be vaccinated according to a 0,2,6-month schedule
* 4 subjects will receive hepatitis B vaccine comparator:

* 2 will be vaccinated according to a 0,2,4-month schedule
* 2 will be vaccinated according to a 0,2,6-month schedule
3. Group 3 double-blind IP allocation (n=20):

* 16 subjects will receive 100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm.

* 8 will be vaccinated according to a 0,2,4-month schedule
* 8 will be vaccinated according to a 0,2,6-month schedule
* 4 subjects will receive hepatitis B vaccine comparator:

* 2 will be vaccinated according to a 0,2,4-month schedule
* 2 will be vaccinated according to a 0,2,6-month schedule

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hookworm Disease Hookworm Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-dose (0,2,4 months)

10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.

Group Type EXPERIMENTAL

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

Low-dose (0,2,6 months)

10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.

Group Type EXPERIMENTAL

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

Medium-dose (0,2,4 months)

30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.

Group Type EXPERIMENTAL

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

Medium-dose (0,2,6 months)

30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.

Group Type EXPERIMENTAL

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

High-dose (0,2,4 months)

100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.

Group Type EXPERIMENTAL

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

High-dose (0,2,6 months)

100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.

Group Type EXPERIMENTAL

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

Comparator (0,2,4 months)

Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.

Group Type ACTIVE_COMPARATOR

Hepatitis B Vaccine

Intervention Type BIOLOGICAL

Comparator (0,2,6 months)

Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.

Group Type ACTIVE_COMPARATOR

Hepatitis B Vaccine

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Na-GST-1/Alhydrogel

Intervention Type BIOLOGICAL

Na-APR-1 (M74)/Alhydrogel

Intervention Type BIOLOGICAL

Hepatitis B Vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females between 6 and 10 years, inclusive, who are long-term residents of the study area.
2. Good general health as determined by means of the screening procedure.
3. Assumed availability for the duration of the trial (up to 15 months).
4. Willingness of parent or legal guardian for child to participate in the study as evidenced by signing the informed consent document in combination with the child assent form.
5. Negative for hookworm during screening, or if found to be infected with hookworm, has completed a course of three doses of albendazole.

Exclusion Criteria

1. Inability of parent/legal guardian to correctly answer all questions on the informed consent comprehension questionnaire.
2. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies.
3. Known or suspected immunodeficiency.
4. Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 1.25-times the upper reference limit).
5. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than 1+ protein, or more than trace blood on urine dipstick testing with the exception of greater than trace blood detected in females during menses).
6. Laboratory evidence of hematologic disease (absolute leukocyte count \<4500/mm3; absolute leukocyte count \>13.0 x 103/mm3; hemoglobin \<9.5 g/dl; or, platelet count \<140,000/mm3).
7. Other condition that in the opinion of the investigator could jeopardize the safety or rights of a child participating in the trial or would render the child unable to comply with the protocol.
8. Participation in another investigational vaccine or drug trial within 30 days of starting this study or for the duration of the study.
9. History of a severe allergic reaction or anaphylaxis.
10. Severe asthma as defined by the need for daily use of inhalers or emergency room/clinic visit or hospitalization within 6 months of the child's planned first vaccination in the study.
11. Positive for HCV.
12. Positive for HBsAg.
13. Positive for HIV infection.
14. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study or expect to use for the duration of the study.
15. Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.
16. History of a surgical splenectomy.
17. Receipt of blood products within the 6 months prior to entry into the study.
18. Previous receipt of a primary series (three doses according to a 0, 1, and 6 -12 month schedule) of the hepatitis B vaccine.

Minimum Eligible Age

6 Years

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes